Strategic Trust Kelly CRISPR & Gene Editing Technology ETF
XDNA
XDNA was delisted on the 30th of November, 2023.
1 hedge funds and large institutions have $943K invested in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF in 2022 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$971K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $943K | +$971K | +75,069 | New |
|
XDNA Hedge Fund Activity: Q1 2022 in Review
1 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) for Q1 2022, worth a combined $943K.
Buyers outnumbered sellers: 1 fund opened new XDNA positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $971K.
- 1 institutional investor held Strategic Trust Kelly CRISPR & Gene Editing Technology ETF (XDNA) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $943K of Strategic Trust Kelly CRISPR & Gene Editing Technology ETF stock for Q1 2022.
- 1 fund opened new Strategic Trust Kelly CRISPR & Gene Editing Technology ETF positions in Q1 2022 and 0 closed out, a net change of +1 holder.
- The largest Strategic Trust Kelly CRISPR & Gene Editing Technology ETF buyer in Q1 2022 was Jane Street, an estimated $971K added.
Based on aggregated 13F filings for Q1 2022.